Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-12-08 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
2025年第二次临时股东会通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2025 second extraordinary general meeting (临时股东会) of shareholders for 海创药业股份有限公司. It includes information about the meeting date, voting methods, agenda items (such as the proposal to amend the Articles of Association), registration procedures, and proxy authorization. There is no financial data, earnings, or audit information presented. The document is not a report but a formal announcement and invitation to shareholders to attend and vote at the meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-12-08 Chinese
2025年第二次临时股东会会议资料
AGM Information Classification · 95% confidence The document is titled '2025 年第二次临时股东会会议资料' which translates to '2025 Second Extraordinary General Meeting (EGM) Meeting Materials'. It contains detailed information about the meeting agenda, voting procedures, shareholder rights, and a specific proposal regarding amendments to the company's articles of association (company charter). The document is a comprehensive set of materials prepared for the shareholders to review before or during the EGM. It is not a report of the meeting results, nor is it a brief announcement or a proxy solicitation. It is also not an annual or interim financial report, nor a regulatory filing or certification. The content aligns with the definition of AGM Information (AGM-R), which includes presentations and materials shared during general meetings, including extraordinary meetings. The document length is 3801 characters, which is consistent with a meeting material document rather than a short announcement. Therefore, the correct classification is AGM Information (AGM-R).
2025-12-08 Chinese
自愿披露关于氘恩扎鲁胺软胶囊纳入2025年国家医保药品目录的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company 海创药业股份有限公司 regarding the inclusion of their drug 氘恩扎鲁胺软胶囊 into the 2025 National Medical Insurance Drug Catalog. It details the drug's clinical background, market impact, and the company's plans following this inclusion. The document is relatively short (1660 characters) and serves as a formal disclosure of a significant business development rather than a financial report or regulatory filing. It does not contain financial statements, audit information, or management changes. It is an announcement about a business event impacting the company, specifically related to product listing and market access. This type of announcement fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-07 Chinese
自愿披露关于口服PROTAC药物HP518片联合抗肿瘤药物治疗晚期前列腺癌获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by the company HaiChuang Pharmaceutical Co., Ltd. regarding the approval of a clinical trial for their oral PROTAC drug HP518 for treating advanced prostate cancer. It includes details about the drug, regulatory approval from the National Medical Products Administration, clinical trial phases, and risk warnings. The document is an official announcement of a regulatory approval event and does not contain financial statements, management discussion, or detailed financial data. It is not a report like an annual or interim report, nor is it a call transcript or governance document. It fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about clinical trial approval and related information that does not fit other specific categories.
2025-11-24 Chinese
关于召开2025年第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2025 third quarter earnings explanation meeting (业绩说明会), including time, location, participants, and how investors can participate and ask questions. It references the prior release of the 2025 third quarter report but does not contain any financial data or results itself. The document is short (1470 characters) and serves as a notice for an upcoming investor presentation event rather than the presentation or report itself. Therefore, it fits best as an Investor Presentation (IP) announcement or a meeting notice. Given the detailed description of the meeting and investor interaction, the classification is Investor Presentation (IP).
2025-11-06 Chinese
自愿披露关于治疗代谢相关脂肪性肝炎（MASH）药物HP515临床II期试验完成首批参与者入组的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a pharmaceutical company about the completion of the first batch enrollment in a Phase II clinical trial for a drug treating metabolic associated steatohepatitis (MASH). It contains detailed information about the drug, clinical trial progress, market data, and risk warnings. There are no financial statements, earnings data, or regulatory filings related to financial performance. The document is an announcement of a clinical trial milestone and related information, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive content rather than just a notice of report availability. Therefore, the document best fits the category of a general regulatory announcement or compliance disclosure that does not fit other specific categories, which corresponds to Regulatory Filings (RNS).
2025-11-04 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.